Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Waldenström's Macroglobulinemia Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Waldenström's Macroglobulinemia
Interventions
Ibrutinib, Placebo, Rituximab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
Interventions
Entospletinib, Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
La Jolla, California • Long Beach, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced May 22, 2026, 12:05 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
126
States / cities
Tucson, Arizona • Coral Gables, Florida • Coral Springs, Florida + 92 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
Interventions
Carfilzomib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced May 22, 2026, 12:05 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Interventions
Sonrotoclax, Zanubrutinib
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma, Waldenstrom Macroglobulinemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
SNS-062
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Orange, California • San Diego, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced May 22, 2026, 12:05 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Interventions
Pirtobrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Waldenström's Macroglobulinemia
Interventions
BGB-3111, Ibrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • Duarte, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Waldenström's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Carfilzomib, Rituximab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 22, 2026, 12:05 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Interventions
ZEN003365
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Hematological Malignancies
Interventions
KPT-330
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced May 22, 2026, 12:05 AM EDT